In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid
Yamada H, Yoshida M, Nakano Y, Suganami T, Satoh N, Mita T, Azuma K, Itoh M, Yamamoto Y, Kamei Y, Horie M, Watada H, Ogawa Y
Arteriosclerosis, thrombosis, and vascular biology · 88 citas
Etiquetas de revisión
Financiación no declaradaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas, más trabajo en animales o laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2008-10-24 · Arterioscler Thromb Vasc Biol · vol. 28 · número 12 · págs. 2173–2179
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 112 citas · más que el 93% de estudios similares · 4.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 43 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Atherosclerosis and Cardiovascular Diseases · Cell Adhesion Molecules Research
- Palabras clave
- eicosapentaenoic acid, monocyte adhesion, endothelial cells, endothelial adhesion molecules, VCAM-1, ICAM-1, nuclear factor-kappaB, lipopolysaccharide, aortic endothelium, metabolic syndrome, omega-3 fatty acids, statin therapy, coronary events
- MeSH
- aorta, monocytes, cells, cultured, endothelial cells, animals, humans, mice, obesity, lipopolysaccharides, eicosapentaenoic acid, fatty acids, unsaturated, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, microscopy, confocal, immunohistochemistry, prospective studies, cell adhesion, active transport, cell nucleus, middle aged, female, male, atherosclerosis, transcription factor rela, in vitro techniques, metabolic syndrome
13 autores
- Hideto Yamada🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Masayuki Yoshida🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Yasutaka Nakano🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Takayoshi Suganami🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Noriko Satoh🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Tomoya Mita🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Kosuke Azuma🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Michiko Itoh🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Yukio Yamamoto🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Yasutomi Kamei🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Minoru Horie🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Hirotaka Watada🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
- Yoshihiro Ogawa🇯🇵Tokyo Medical and Dental University; Shiga University of Medical Science; Kyoto Medical Center; Juntendo University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
A large-scale, prospective, randomized clinical trial has recently revealed that the addition of highly purified eicosapentaenoic acid (EPA) to low-dose statin therapy significantly reduces the incidence of major coronary events. Here we investigated in vivo and in vitro effect of EPA on monocyte adhesion to endothelial cells and adhesion molecules.
Methods and results
A new en face immunohistochemistry of endothelial surface in combination with confocal microscopy revealed marked reduction of lipopolysaccharide (LPS)-induced monocyte adhesion to the aortic endothelium in parallel with the suppression of vascular cell adhesion molecule 1 (VCAM-1) and nuclear translocation of nuclear factor-kappaB p65 in EPA-treated mice relative to vehicle-treated groups. In an in vitro adhesion assay system under physiological flow conditions, EPA inhibited LPS-induced monocyte adhesion and endothelial adhesion molecules. We found significant decrease in plasma concentrations of soluble intercellular adhesion molecule 1 (sICAM-1) and sVCAM-1 in patients with the metabolic syndrome after a 3-month administration of highly purified EPA (1.8 g daily). Multivariate regression analysis revealed that EPA administration is the only independent determinant of sICAM-1 and sVCAM-1.
Conclusions
This study provides evidence that EPA inhibits monocyte adhesion to endothelial cells in parallel with the suppression of endothelial adhesion molecules in vivo and in vitro.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.